Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

207.77
-0.2600-0.12%
Post-market: 207.770.00000.00%19:30 EDT
Volume:734.95K
Turnover:153.13M
Market Cap:10.88B
PE:-55.13
High:210.87
Open:207.22
Low:206.50
Close:208.03
52wk High:260.19
52wk Low:112.90
Shares:52.38M
Float Shares:43.83M
Volume Ratio:1.37
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:130.64
PE(LYR):-56.43

Loading ...

Axsome Therapeutics Hosts Auvelity® FDA Approval Investor Event Featuring Expert Thought Leader

THOMSON REUTERS
·
May 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 01

U.S. RESEARCH ROUNDUP-Caterpillar, Textron, Wesco International

Reuters
·
May 01

Assessing Axsome Therapeutics (AXSM) Valuation After Recent Share Price Momentum

Simply Wall St.
·
May 01

Axsome Therapeutics price target raised to $217 from $207 at Morgan Stanley

TIPRANKS
·
May 01

Axsome Therapeutics given ‘clean label’ for Auvelity in ADA, says TD Cowen

TIPRANKS
·
May 01

US FDA approves Axsome's drug for Alzheimer's-related agitation

Reuters
·
May 01

Axsome Therapeutics Announces FDA Approval of Auvelity® (Dextromethorphan Hbr and Bupropion Hcl) for the Treatment of Agitation Associated With Dementia Due to Alzheimer’s Disease

THOMSON REUTERS
·
May 01

NASDAQ TRADE HALT HALT NEWS PENDING AT 02:03 PM

Reuters
·
May 01

Mizuho Securities Adjusts Axsome Therapeutics Price Target to $228 From $230, Maintains Outperform Rating

MT Newswires Live
·
Apr 28

Axsome Therapeutics Inc : Mizuho Cuts Target Price to $228 From $230

THOMSON REUTERS
·
Apr 28

Earnings Preview: Axsome Therapeutics revenue is expected to increase by 59.11%, and institutional views are broadly bullish

Earnings Agent
·
Apr 27

Axsome Therapeutics announces annual shareholder meeting via virtual webcast

Reuters
·
Apr 25

Axsome Chief Commercial Officer Ari Maizel disposes of common shares worth $1.37 million

Reuters
·
Apr 24

Axsome Therapeutics Facing 'Attractive Setup' Ahead of Auvelity's Label Expansion Decision, Oppenheimer Says

MT Newswires Live
·
Apr 21

Axsome Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Apr 11

Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says

MT Newswires Live
·
Apr 10

UBS Adjusts Axsome Therapeutics Price Target to $259 From $251, Maintains Buy Rating

MT Newswires Live
·
Apr 10

Jefferies Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

TIPRANKS
·
Apr 09

Axsome Therapeutics: Auvelity’s Best‑in‑Class Potential in Alzheimer’s Agitation Supports Buy Rating

TIPRANKS
·
Apr 09